Amgen Stock

$294.76

1.17% day before yesterday

NYSE, Jul 18, 10:03 pm CET

ISIN

US0311621009

Symbol

AMGN

Reports

Quarter | Annual

Index

Dow Jones, NASDAQ-100

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Amgen Stock price

$294.76

+33.81 12.96% 5Y

NYSE, Closing price Fri, Jul 18 2025

-3.49 1.17%

ISIN

US0311621009

Symbol

AMGN

Reports

Quarter | Annual

Index

Dow Jones, NASDAQ-100

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$158.5b

Enterprise Value

$207.1b

Net debt

$48.6b

Cash

$8.8b

Shares outstanding

537.7m

Valuation (TTM | estimate)

P/E

26.9 | 13.8

P/S

4.6 | 4.4

EV/Sales

6.1 | 5.8

EV/FCF

19.0

P/B

25.5

Dividends

DPS

$9.00

Yield 1Y | 5Y

3.1% | 3.1%

Growth 1Y | 5Y

5.6% | 9.2%

Payout 1Y | 3Y

119.1% | 78.6%

Increased

14 Years

Financials (TTM | estimate)

Revenue

$34.1b | $36.0b

EBITDA

$14.2b | $20.8b

EBIT

$8.6b | $15.9b

Net Income

$5.9b | $11.5b

Free Cash Flow

$10.9b

Growth (TTM | estimate)

Revenue

15.6% | 7.7%

EBITDA

22.0% | 36.2%

EBIT

22.0% | 64.7%

Net Income

57.7% | 180.0%

Free Cash Flow

53.8%

Financial Health

Equity Ratio

6.4%

Return on Equity

69.6%

ROCE

13.0%

ROIC

Debt/Equity

9.2

EPS

$11.0

FCF per Share

$20.3

Short interest

2.5%

Employees

28k

Rev per Employee

$1.2m

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

39 Analysts have issued a Amgen forecast:

21x Buy

54%

15x Hold

38%

More details on Analyst Estimates Including Price Targets

39 Analysts have issued a Amgen forecast:

Buy

54%

Hold

38%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	34,126 34,126	16% 16% 100%
- Direct Costs	12,263 12,263	23% 23% 36%
Gross Profit	21,863 21,863	12% 12% 64%
- Selling and Administrative Expenses	6,975 6,975	4% 4% 20%
- Research and Development Expense	6,107 6,107	21% 21% 18%
EBITDA	14,188 14,188	22% 22% 42%
- Depreciation and Amortization	5,580 5,580	22% 22% 16%
EBIT (Operating Income) EBIT	8,608 8,608	22% 22% 25%
Net Profit	5,933 5,933	58% 58% 17%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Amgen Stock News

Neutral

Seeking Alpha

●

2 days ago

Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More

This week's Undercovered Dozen spotlights 12 lesser-known stocks with compelling investment theses, spanning micro-nuclear, luxury, biotech, and high-yield BDCs. Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's explosive growth in ophthalmic pharmaceuticals. Coca-Cola and Ares Capital are flagged as overvalued or increasing...

Positive

Seeking Alpha

●

5 days ago

Key acquisitions since 2022 increased Amgen's rare disease pipeline and footprint in the market, with the company poised to benefit from the rare disease market's 10.35% CAGR up to 2037. A growing portfolio of biosimilar products will drive double-digit sales growth in the coming decade. The immense growth potential in both its rare disease and biosimilar portfolios is essential for Amgen to of...

Positive

Seeking Alpha

●

5 days ago

Amgen: Great Starting Yield For This Wealth Compounder

Amgen offers an economic moat with patent protection, a robust pipeline, and strong execution, making it a defensive long-term investment. Double-digit sales growth in key drugs and a burgeoning biosimilars business support Amgen's solid revenue and earnings outlook. The pipeline, especially MariTide for obesity and biosimilars to blockbuster oncology drugs, provides meaningful future growth ca...

More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office	United States
CEO	Robert Bradway
Employees	28,000
Founded	1980
Website	www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now